Using artificial intelligence (AI) to treat thrombotic conditions

What happens when patients become partners in shaping clinical research? In this episode of the ISTH Pulse Podcast, host Dr. Julia Sandrin Gauer is joined by Dr. Sudeep Shivakumar and patient advocate Carol West to explore the role of patient perspectives in the EPCAT III trial, a Canadian-led study examining strategies to prevent venous thromboembolism (VTE) following hip and knee replacement surgery. The discussion highlights the collaboration between the EPCAT III research team and the CanVECTOR Patient Partners Platform, exploring how lived experiences can inform research priorities, trial design and clinical decision-making. Tune in to learn why bringing the patient voice into research matters and how meaningful collaboration can help shape future studies.

Women can face unique blood clot risks across different stages of life, from hormonal contraception and pregnancy to the postpartum period and menopause. But there are still gaps in recognition and diganosis. In a special World Thrombosis Day episode of the ISTH Pulse Podcast, host Dr. Geoffrey Barnes is joined by experts Dr. James Douketis and Dr. Angela Weyand to ask an important question: Are we missing the warning signs? Together, they discuss where progress has been made, where gaps remain and what healthcare professionals can do to better recognize and address thrombosis risks in women. The conversation also explores broader challenges in women’s health, opportunities to improve research and clinical care and why this topic is at the center of the World Thrombosis Day campaign. Learn more and find resources at: https://www.worldthrombosisday.org/women-blood-clots/

In episode 3 of this ISTH Pulse Podcast miniseries, experts explore why next-generation mimetic therapies may be needed in hemophilia A and what they could add to an already evolving treatment landscape. The discussion examines how well current prophylactic options control bleeding, where treatment burden and unmet needs remain and whether less-frequent, subcutaneous dosing could support greater treatment convenience, adherence and access. Our experts also considers how factor VIII inhibitor status may influence treatment decisions and which patients could potentially benefit most as new mimetic therapies continue to develop.

In the second episode of a special ISTH Pulse Podcast miniseries, experts explore why next-generation factor mimetics are being developed for hemophilia A and what unmet needs they may help address. The discussion examines the effectiveness of current prophylactic options, ongoing treatment burden and the potential role of less frequent, subcutaneous therapies in supporting treatment adherence and access. The episode also considers how factor VIII inhibitor status may influence treatment needs and what emerging factor mimetics could mean for the evolving hemophilia treatment landscape.

In this first episode of a special ISTH Pulse Podcast miniseries, the discussion explores why next-generation mimetic therapies may be needed and where current treatment approaches may still leave gaps. The conversation examines whether existing prophylaxis provides adequate bleeding control, how treatment burden and less-frequent subcutaneous dosing may affect adherence and access and how factor VIII inhibitor status can influence treatment decisions. Tune in for a focused look at the evolving therapeutic landscape and the considerations shaping future approaches to hemophilia care.